These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36327699)

  • 21. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
    Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
    Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B7-H3 and its role in bone cancers.
    He L; Li Z
    Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B7-H3 role in the immune landscape of cancer.
    Castellanos JR; Purvis IJ; Labak CM; Guda MR; Tsung AJ; Velpula KK; Asuthkar S
    Am J Clin Exp Immunol; 2017; 6(4):66-75. PubMed ID: 28695059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
    Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
    Front Immunol; 2021; 12():691741. PubMed ID: 34211478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B7-H3/CD276 and small-cell lung cancer: What's new?
    Fabrizio FP; Muscarella LA; Rossi A
    Transl Oncol; 2024 Jan; 39():101801. PubMed ID: 37865049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B7-H3 Immune Checkpoint Protein in Human Cancer.
    Flem-Karlsen K; Fodstad Ø; Nunes-Xavier CE
    Curr Med Chem; 2020; 27(24):4062-4086. PubMed ID: 31099317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.
    Zheng M; Yu L; Hu J; Zhang Z; Wang H; Lu D; Tang X; Huang J; Zhong K; Wang Z; Li Y; Guo G; Liu S; Tong A; Yang H
    Transl Oncol; 2020 May; 13(5):100770. PubMed ID: 32298986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature.
    Wu S; Hu C; Hui K; Jiang X
    Front Oncol; 2024; 14():1408051. PubMed ID: 38952550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
    Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
    Front Oncol; 2021; 11():659662. PubMed ID: 34868903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development.
    Picarda E; Galbo PM; Zong H; Rajan MR; Wallenius V; Zheng D; Börgeson E; Singh R; Pessin J; Zang X
    Sci Adv; 2022 Apr; 8(17):eabm7012. PubMed ID: 35476450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
    Tian M; Cheuk AT; Wei JS; Abdelmaksoud A; Chou HC; Milewski D; Kelly MC; Song YK; Dower CM; Li N; Qin H; Kim YY; Wu JT; Wen X; Benzaoui M; Masih KE; Wu X; Zhang Z; Badr S; Taylor N; Croix BS; Ho M; Khan J
    J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35852863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibiting PP2A Upregulates B7-H3 Expression and Potentially Increases the Sensitivity of Malignant Meningiomas to Immunotherapy by Proteomics.
    Hu B; Hao S; Miao Y; Deng Y; Wang J; Wan H; Zhang S; Ji N; Feng J
    Pathol Oncol Res; 2022; 28():1610572. PubMed ID: 36203966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
    Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
    J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroblastoma: an ongoing cold front for cancer immunotherapy.
    Kennedy PT; Zannoupa D; Son MH; Dahal LN; Woolley JF
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37993280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
    Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
    Front Immunol; 2014; 5():56. PubMed ID: 24575100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
    Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
    Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies.
    Marrella A; Dondero A; Aiello M; Casu B; Olive D; Regis S; Bottino C; Pende D; Meazza R; Caluori G; Castriconi R; Scaglione S
    Front Immunol; 2019; 10():1876. PubMed ID: 31447858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.